Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer at Cellectar Biosciences, will participate in panel discussions and present at multiple medical meetings and industry conferences in September.

Details are as follows:

ADC and Novel Conjugates Partnering and Investment Summit

Title: ADCs x Radioligands: The Use of One Technology to Advance the Other
Date/Time: September 9, 2025, 9:30 AM ET


BioProcess International

Title: ADCs and Beyond in Radiopharmaceuticals
Date/Time: September 15, 2025, 11:30 AM ET


Targeted Radiopharmaceuticals (TRP) Supply Chain and Manufacturing

Title: Addressing Barriers in Supply Chains to Ensure Reliable Isotope Access & Consistent Patient Delivery
Date/Time: September 24, 2025, 9:30 AM ET
Title: Addressing Facility Downtime & Regulatory Delays by Designing Robust Infrastructure Strategy to Accelerate Safe, Scalable Radiopharmaceutical Manufacturing
Date/Time: September 24, 2025, 12:10 PM ET
Title: Impact of Isotope Half-Life: Long-vs. Short-Lived Radiotherapeutics and Differences in Manufacturing, Quality & Distribution to Clinic
Date/Time: September 24, 2025, 1:30 PM ET


American Association for Cancer Research Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer – From Biology to Breakthrough Therapies

Title: Precision Radiotherapy for Incurable Brain Tumors: Phase 1b Dose & Regimen Optimization Study of Iopofosine I 131 in Inoperable Relapsed or Refractory Pediatric High-Grade Glioma, Interim Data Assessment
Session: Plenary Session 3: From Targets to Trials: Rethinking How We Design Child-First Medicine
Date/Time: September 26, 2025, 2:50 PM ET


American Association for Cancer Research Special Conference in Cancer Research: Advances in Pancreatic Cancer Research – Emerging Science Driving Transformative Solutions

Title: Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225, a Novel Actinium-Based Radio-Conjugate
Date/Time: September 30, 2025, 6:00 – 9:00 PM ET


About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.

The company's product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company's social media channels: X , LinkedIn , and Facebook .

Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

CLRB
The Conversation (0)
Cellectar Biosciences Inc.

Cellectar Biosciences Inc.

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Bold Ventures Announces Prospecting and Sampling Results and Mobilizes Crew to Burchell Gold and Copper Project

Bold Ventures Announces Prospecting and Sampling Results and Mobilizes Crew to Burchell Gold and Copper Project

Bold Ventures Inc. (TSXV: BOL,OTC:BVLDF) (the "Company" or "Bold") is pleased to announce the results of a prospecting and sampling program on its Burchell Gold and Copper Property (the "Property"), located within the Shebandowan Greenstone Belt, approximately 100 km west of Thunder Bay, Ontario. 209 grab samples and 42 channel samples were collected in total. The goal of this phase of work was preparation for a mechanical stripping, sampling and geological mapping program at the 111 Zone gold showing and surroundings. A crew has been mobilized for the mechanical stripping program which will commence immediately.

Highlights from the program include:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Heritage Mining Plans Aggressive Program at Zone 3 Extension Mega-Quartz Vein System at its Flagship Drayton-Black Lake Project

Heritage Mining Plans Aggressive Program at Zone 3 Extension Mega-Quartz Vein System at its Flagship Drayton-Black Lake Project

/ NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Quetzal Copper Announces Refiling of June 30, 2025 Financial Statements

Quetzal Copper Announces Refiling of June 30, 2025 Financial Statements

Quetzal Copper Ltd. (TSXV: Q,OTC:QTZCF) ("Quetzal" or the "Company") announces that it has refiled its interim financial statements and management's discussion and analysis ("MD&A") for the three and six months ended June 30, 2025 (the "Q2 2025 Financial Statements"). The original filings were made on August 28, 2025.

The amendment was made to correct and clarify disclosure relating to the Company's share-based compensation. The Q2 2025 financials originally filed on August 28, 2025 did not reflect the correct number of options and warrants outstanding, and the share-based compensation related to the January 15, 2025 option grant was not accounted for. In this refiling, the correct number of outstanding options and warrants and the share-based compensation related to the January 15, 2025 option grant have now been properly reflected and accounted.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Two Pools Project expands with new tenement applications

Two Pools Project expands with new tenement applications

Corazon Mining (CZN:AU) has announced Two Pools Project expands with new tenement applications

Download the PDF here.

Angkor Resources Receives Approval to Incorporate Mussel Basin into Block VIII Oil and Gas License, Cambodia

Angkor Resources Receives Approval to Incorporate Mussel Basin into Block VIII Oil and Gas License, Cambodia

(TheNewswire)

GRANDE PRAIRIE, ALBERTA (September 10, 2025) TheNewswire - Angkor Resources Corp. (TSXV: ANK,OTC:ANKOF) ("ANGKOR" OR "THE COMPANY") announces its subsidiary, EnerCam Resources Co. Ltd. (Cambodia) ("EnerCam") has received approval from government authorities of Ministry of Mines and Energy for an additional 220 square kilometers added within the Block VIII boundaries, referred to as the Mussel Basin.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×